Kwang-Hun Lee MD, Presenter: Nothing to Disclose

Eleni A. Liapi MD, Abstract Co-Author: Nothing to Disclose

Veronica Prieto Ventura MD, Abstract Co-Author: Nothing to Disclose

Manon Buijs MD, Abstract Co-Author: Nothing to Disclose

Josephina Anna Vossen MD, Abstract Co-Author: Nothing to Disclose

Mustafa Vali MD, Abstract Co-Author: Nothing to Disclose

Jean-Francois H. Geschwind MD, Abstract Co-Author: Consultant, MDS Inc Grant, MDS Inc Consultant, Biocompatibles International plc Grant, Biocompatibles International plc Research support, Genentech, Inc Grant, Boston Scientific Corporation Consultant, BioSphere Medical, Inc Grant, BioSphere Medical, Inc

To evaluate material characteristics of three different types of embolic materials by detecting trends of systemic doxorubicin/doxorubicinol release and tissue uptake after TACE using the Vx-2 tumor rabbit model.

Fifteen NZ white rabbits were randomly assigned in three groups (five rabbits in each group). Three different types of embolic materials (Group I with M077-55-2, Group II with M077-55-3 and Group III with M077-55-4) with different degrees of shpericity, porosity and compressibility, but with similar size, were blindly evaluated. TACE was performed with injection the mixture of doxorubicin and iodized oil (0.5 mL) followed by the embolic material (0.5 mL). Plasma concentration of doxorubicin and doxorubicinol were analyzed at various time points (20, 40, 60, 120 minutes and 2 days). Animals were sacrificed two days after TACE and tissue samples of liver and tumor were obtained for doxorubicin concentration analysis.

All embolic materials showed similar pattern of plasma doxorubicin and doxorubicinol release and doxorubicin tissue concentration at various time intervals. There were no statistical differences (p>0.05) between the three groups for systemic plasma concentration of doxorubicin and doxorubicinol as well as doxorubicin tumor and liver concentrations. M077-55-2 was commercially available Contour SE, and the other M077-55-3 and M077-55-4 were research-based Contour prototype materials with similar size to Contour SE but different sphericity, porosity and compressibility.

During TACE, our in-vivo study suggests that there are no significant differences between the three types of tested micropsheres for plasma drug release and tissue uptake.

Test of various embolic materials before applicate human liver cancer embolization.

Lee, K, Liapi, E, Prieto Ventura, V, Buijs, M, Vossen, J, Vali, M, Geschwind, J, Evaluation of Three Types of Microspheres with Different Material Characteristics by Transcatheter Arterial Chemoembolization (TACE) in the Vx-2 Liver Tumor Rabbit Model.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5013441.html